Search clinical trials for: imatinib Mesylate

Total 1351 results

Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Gastric Cancer

China
ViiV Healthcare

Completed

A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults

HIV Infections

Spain, France, United States, Germany, Italy, South Africa
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)

Prostatic Hyperplasia

Philippines
Peking University Cancer Hospital & Institute
Peking University First Hospital; Shanxi Province Cancer Hospital; Peking University... and other collaborators

Completed

Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)

Breast Cancer
Institut Bergonié

Completed

Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (CYCLIGIST)

Advanced Gastrointestinal Stromal Tumors

France
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

NSCLC

China
Eisai Limited

Completed

A Confirmation Study of Eribulin in Combination With Capecitabine

Metastatic Breast Cancer

United Kingdom, Bulgaria, Russian Federation
Peking University People's Hospital

Completed

Apatinib for Inoperable Advanced Chondrosarcoma (AIAC)

Efficacy | Toxicity, Drug

China
Novartis Pharmaceuticals

Completed

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

Netherlands, Italy, France, United Kingdom
Eisai Co., Ltd.

Completed

Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

Biliary Tract Cancer

Japan
Zhou Fuxiang
Hubei Cancer Hospital; Shiyan Taihe Hospital; Huangshi Central Hospital, China; Xianning Central Hospital and other collaborators

Unknown

The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer

Metastatic Gastric Cancer

China
Tianjin Medical University Second Hospital

Unknown

A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）

Small Cell Lung Cancer Extensive Stage

China
AB Science

Completed

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

Gastrointestinal Stromal Tumors

United States, France, Netherlands, Italy
Radboud University Medical Center

Terminated

Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy (ABILITY)

Gastrointestinal Stromal Tumor | Major Gastrectomy

Netherlands
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia

Japan
Sun Yat-sen University

Completed

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

Ovarian Cancer

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Second-line Treatment

China
Beijing Friendship Hospital

Completed

Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer

Gastric Cancer
The First Affiliated Hospital of Xiamen University

Unknown

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

Locally Advanced or Metastatic Gastric Adenocarcinoma

China
Qianfoshan Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Unknown

Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer

Immune Checkpoint Inhibition

China
St. Jude Children's Research Hospital
National Cancer Institute (NCI)

Completed

Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Lymphoblastic Leukemia, Acute

United States
European Organisation for Research and Treatment...

Withdrawn

Long-term Surival of GIST Patients ≥ 10 Years on Imatinib

GIST
Beijing Tsinghua Chang Gung Hospital

Unknown

Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer

Hepatocellular Carcinoma
The First Affiliated Hospital with Nanjing Medical...
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Unknown

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma (HCC-009)

Hepatocellular Carcinoma

China
Versailles Hospital

Unknown

IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS. (IMAGE-19)

SARS Virus

France
First Affiliated Hospital of Harbin Medical University

Terminated

Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer

Ovarian Cancer

China
Case Comprehensive Cancer Center

Completed

Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate

Metastatic Breast Cancer | Brain Metastases

United States
University of Washington
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Hepatic Impairment

United States
Eisai Inc.
Halozyme Therapeutics

Terminated

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer

United States
Asan Medical Center
Hanmi Pharmaceutical Company Limited

Completed

L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors (GISTs)

Korea, Republic of
Eisai Inc.

Completed

E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Metastatic Breast Cancer

Poland, Ukraine, United States, Taiwan, Spain, Argentina, Bulgaria, Romania, South Africa, Australia, Canada, Singapore, Russian Federation, Brazil, Germany, Hungary, Italy, Israel, Greece, Mexico, Belgium, Czechia, France
Gyeongsang National University Hospital

Unknown

Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia

COVID-19 | Corona Virus Infection
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function

Subjects With Impaired Renal Function and Healthy Subjects
Peking University Cancer Hospital & Institute

Unknown

Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

Melanoma
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

Recurrent Osteosarcoma

United States, Canada
Peking University People's Hospital
Peking University Shougang Hospital; Peking University International Hospital

Withdrawn

Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial

Advanced Cancer | Soft Tissue Sarcoma Adult

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

PD-L1 Positive Non-small Cell Lung Cancer
Foresee Pharmaceuticals Co., Ltd.

Completed

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

Prostatic Neoplasms

Korea, Republic of, United States, Lithuania, Slovakia, Czechia
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Lung Cancer

United States
Sheba Medical Center

Unknown

Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus (COSTA)

COVID - 19

Israel
Zhongshan Hospital Xiamen University

Unknown

Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer

Hepatic Metastasis of Colorectal Cancer

China
Beijing Friendship Hospital

Unknown

Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer

Gastric Cancer

China
NCIC Clinical Trials Group

Completed

Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Canada
Eisai Co., Ltd.

Completed

A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas (HAL03T)

Sarcoma, Soft Tissue

Japan
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma

Lung Cancer

United States
R&D Cardiologie
St. Antonius Hospital

Unknown

What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2. (WOEST 2)

Myocardial Infarction | Stroke | Bleeding | Acute Coronary Syndromes | Coronary Artery Diseases | Atrial Fibrillations | Heart Valve Prostheses

Belgium, Netherlands
Eisai Korea Inc.

Completed

Halaven Post-Marketing Surveillance (PMS)

Breast Cancer

Korea, Republic of
Ottawa Hospital Research Institute
Pfizer

Completed

A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc (RIFAMARA)

HIV Infection | HIV-1 Infection | Mycobacterium Avium Complex (MAC)

Canada
Novartis Pharmaceuticals

Completed

A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation (ENESTgoal)

CML

United States

3

Subscribe